Studies & Results
TRIO035
A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (MT-5111-001)
View FDA Study
Presentations
SABCS 2019
A Novel HER2-Targeting Engineered Toxin Body Under Clinical Development to Overcome Mechanisms of Resistance to Existing HER2-Targeted Therapies
ASCO GI 2021
Van Tine BA, et al.
A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.
AACR 2021
Wainberg ZA, et al.
Phase 1 study of the novel immunotoxin MT-5111 in patients (pts) with HER-2+tumors
SABCS 2021
Van Tine BA, et al.
Interim Results of a Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors
ASCO GI 2022
Hubbard JM, Van Tine BA, et al.
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
ASCO 2022
Hubbard JM, et al.
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
SABCS 2019
A Novel HER2-Targeting Engineered Toxin Body Under Clinical Development to Overcome Mechanisms of Resistance to Existing HER2-Targeted Therapies
ASCO GI 2021
Van Tine BA, et al.
A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors.
AACR 2021
Wainberg ZA, et al.
Phase 1 study of the novel immunotoxin MT-5111 in patients (pts) with HER-2+tumors
SABCS 2021
Van Tine BA, et al.
Interim Results of a Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors
ASCO GI 2022
Hubbard JM, Van Tine BA, et al.
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
ASCO 2022
Hubbard JM, et al.
A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org